The initiative could tackle the first-mover disadvantage some CDMOs believe deters early customers, but leaders at companies ...
An FDA draft guidance nixing the requirement for biosimilar manufacturers to conduct comparative efficacy studies may prove ...
Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the ...
With the 2024 election in the rearview mirror and the dust settling nationally and here in the state, we must make clear that in Colorado we believe in good governance and take fulfilling our ...
The U.S. Food and Drug Administration (FDA) announced that it aims to increase the agency’s use of artificial intelligence (AI) across its centers to accelerate scientific reviews by June 30, 2025.
"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are ...
It takes 10–15 years and hundreds of millions of dollars for a pharmaceutical company to navigate the Food and Drug Administration (FDA) regulatory process and bring a new drug to market. Many ...
The Food and Drug Administration (FDA) development and approval process for drugs and medical devices involves multiple phases that ensure the safety and effectiveness of products before and after ...
It takes 10–15 years and hundreds of millions of dollars for a pharmaceutical company to navigate the Food and Drug Administration (FDA) regulatory process and bring a new drug to market. Many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results